Cargando…
The role of aflibercept in the management of diabetic macular edema
Diabetic macular edema (DME) represents one of the leading causes of visual impairment in working-age adults. Although there are several proven treatments available for this condition, pharmacotherapy through the use of intravitreal antivascular endothelial growth factor agents has revolutionized th...
Autores principales: | Chang, Andrew A, Hong, Thomas, Ewe, Shaun Y, Bahrami, Bobak, Broadhead, Geoffrey K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532215/ https://www.ncbi.nlm.nih.gov/pubmed/26273198 http://dx.doi.org/10.2147/DDDT.S62778 |
Ejemplares similares
-
The clinical utility of aflibercept for diabetic macular edema
por: Stewart, Michael W
Publicado: (2015) -
The efficacy and safety of aflibercept and conbercept in diabetic macular edema
por: Cai, Siwei, et al.
Publicado: (2018) -
Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
por: Klein, Kendra A., et al.
Publicado: (2017) -
Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
por: Lim, Laurence S, et al.
Publicado: (2015) -
Management of macular edema due to central retinal vein occlusion – The role of aflibercept
por: Rhoades, William, et al.
Publicado: (2017)